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In the brain, astrocytes represent the cellular population that expresses the highest
amount of connexins (Cxs). This family of membrane proteins is the molecular
constituent of gap junction channels and hemichannels that provide pathways for direct
cytoplasm-to-cytoplasm and inside-out exchange, respectively. Both types of Cx channels
are permeable to ions and small signaling molecules allowing astrocytes to establish
dynamic interactions with neurons. So far, most pharmacological approaches currently
available do not distinguish between these two channel functions, stressing the need to
develop new specific molecular tools. In astrocytes two major Cxs are expressed, Cx43
and Cx30, and there is now evidence indicating that at least Cx43 operates as a gap
junction channel as well as a hemichannel in these cells. Based on studies in primary
cultures as well as in acute hippocampal slices, we report here that Gap19, a nonapeptide
derived from the cytoplasmic loop of Cx43, inhibits astroglial Cx43 hemichannels in a
dose-dependent manner, without affecting gap junction channels. This peptide, which not
only selectively inhibits hemichannels but is also specific for Cx43, can be delivered in vivo
in mice as TAT-Gap19, and displays penetration into the brain parenchyma. As a result,
Gap19 combined with other tools opens up new avenues to decipher the role of Cx43
hemichannels in interactions between astrocytes and neurons in physiological as well as
pathological situations.
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INTRODUCTION
Compared to neurons, astrocytes make up the brain cell pop-
ulation that expresses the highest amount of the gap junc-
tion proteins, named connexins (Cxs) (Ransom and Giaume,
2013). Connexin-mediated channel functions are essential for the
dynamic and metabolic interactions that astrocytes establish with
each other and at their interfaces with neurons and the vascula-
ture (Giaume et al., 2010). Indeed, transgenic animals in which
the two major astroglial Cxs, i.e., Cx43 and Cx30, have been
deleted, exhibit impaired potassium clearance, synaptic transmis-
sion and plasticity (Wallraff et al., 2006; Pannasch et al., 2011), a
dysmyelinating phenotype (Lutz et al., 2009) and a loss in blood-
brain barrier integrity (Ezan et al., 2012). However, the exclusive
use of such animals does not distinguish between the contribu-
tions of the two types of astroglial Cxs as well as between the
channel and hemichannel functions that they support (Giaume
and Theis, 2010). So far, the use of single Cx knock-out mice
has provided key data demonstrating a role of Cx43 in neuronal
migration (Elias et al., 2007; Cina et al., 2009), a synaptic activity-
dependent modulation of Cx30 gap junctions in astrocytes in the
olfactory bulb (Roux et al., 2011) and recently, it was reported that
the lack of Cx30 impacts synaptic transmission through the mod-
ulation of astroglial glutamate transport (Pannasch et al., 2014).
However, there is still a need to develop new pharmacological
tools to design in vitro and in vivo experiments studying the role
of Cxs in astrocytes.
Gap junction channels form junctional plaques that are com-
posed of two docked hemichannels oligomerized from six Cx
protein subunits. Usually, most of the unapposed/non-junctional
hemichannels are closed but a fraction of Cx43 HCs can be open
under resting conditions and have physiological roles (Stehberg
et al., 2012; Chever et al., 2014) while they become more
active in pathological situations (Giaume et al., 2013). Their
activation results in gliotransmitter (ATP, glutamate) release,
the entry of calcium ions (Ca2+) and glucose, ionic imbal-
ance, cellular volume overload and, in certain cases, cell death
(Decrock et al., 2009; De Bock et al., 2013; Giaume et al., 2013).
Currently, there are no tools available that allow selective target-
ing of hemichannels since all known pharmacological blockers,
including glycyrrhetinic acid-derivatives such as carbenoxolone
Frontiers in Cellular Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 306 | 1
CELLULAR NEUROSCIENCE
Abudara et al. Gap19 selectively inhibits astroglial hemichannels
or related molecules with improved blood-brain barrier perme-
ability (Takeuchi et al., 2011), poorly discriminate between gap
junctions and hemichannels. Additionally, they mostly affect Cx
channels composed of various distinct Cx types (Harris, 2001;
Evans et al., 2006; Spray et al., 2006; Saez and Leybaert, 2014).
Beside these derivatives of glycyrrhetinic acid, other compounds
such as gadolinium (Gd3+) and lanthanum (La3+) are supposed
to affect only hemichannels but, especially in the nervous sys-
tem where neurons are present, they have side effects that limit
the interpretation of their use. Connexins are tetraspan mem-
brane proteins that have two extracellular (EL) loops and one
intracellular cytoplasmic loop (CL). Synthetic peptides like Gap26
and Gap27 that mimic a short stretch of amino acids (AAs)
on the extracellular loops have been developed more than two
decades ago to inhibit gap junctional communication (Warner
et al., 1995) (for Gap26 and Gap27 sequences see Figure 1). These
peptides are thought to interact with the extracellular loops and
block hemichannel activity within minutes (Wang et al., 2012;
Giaume et al., 2013). They also prevent the docking of two fac-
ing hemichannels and thus affect gap junctional communication
when applied for periods of several hours (Evans and Boitano,
FIGURE 1 | Position of the Gap19 sequence in the intracellular
cytoplasmic loop domain of human Cx43. One identified interaction site
is located in the last 9 AAs of the CT-tail marked in purple (Wang et al.,
2013a). The sequences of Gap19 (red) on the intracellular loop, Gap26
(green) and Gap27 (blue) on the extracellular loops are indicated on the
drawing. The CT residues marked as green squares are sites of
posttranslational modifications and have been added for illustration
purposes [Illustration generated with the Protter tool (Omasits et al., 2014)].
2001; Decrock et al., 2009). Similarly, antibodies directed against
the EL domains of the Cx protein rapidly inhibit hemichannels
but they also display delayed inhibition of gap junction channels
by preventing the processes of hemichannel docking and de novo
gap junction channel formation (Orellana et al., 2011; Riquelme
et al., 2013). In some cases, distinctive effects on hemichannels
and gap junctions depend on the concentration at which they are
applied: peptide5, which contains a sequence that comprises part
of the Gap27 domain (SRPTEKT), inhibits hemichannels at low
(5μM) concentration while combined gap junction/hemichannel
block is only observed at high (500μM) concentration (O’carroll
et al., 2008).
Here, we describe the effect on astroglial hemichannels of
a peptide, named Gap19, that is identical to a short sequence
present on the intracellular CL domain of Cx43 (Figure 1).
Peptides mimicking CL sequences have been frequently used as
control peptides for gap junction work, since it was shown that
these do not inhibit gap junctional coupling (Evans and Leybaert,
2007). Although this specificity has already been reported for the
cardiac system (Wang et al., 2013b) we think that it is impor-
tant to validate this property for the nervous system. Indeed, this
is particular relevant for the astrocytes because Cx43 hemichan-
nels contribute to “gliotransmission” and can thus be involved in
neuroglial interactions that participate to the control of neuronal
activity and survival (see Giaume et al., 2013). In line with this,
we found that Gap19 did not inhibit gap junction coupling in
astrocytes as measured with dye transfer assays. At the same time,
however, Gap19 strongly inhibited Cx43 hemichannels as exem-
plified by ATP release and dye uptake assays. Finally, we provide
evidence that the TAT version of Gap19 is able to cross the intact
blood-brain barrier indicating that this peptide can be used to
block astroglial Cx43 hemichannel activity when applied through
a vascular route.
MATERIALS AND METHODS
ANIMALS
Cultures and slices were obtained from OF1, C57Bl/6 and GFAP-
eGFP mice. All experiments were performed according to the
European Community Council Directives of November 24, 1986
(86/609/EEC) and all efforts were made to minimize the num-
ber of animals used and their suffering. For the in vivo exper-
iments with TAT-Gap19 all breeding and animal procedures
were approved by The University of British Columbia Animal
Care Committee or Ghent University Animal Experiment Ethical
Committee and performed in accordance with the guidelines
established by the Canadian Council on Animal Care or European
Ethics Committee guidelines.
ASTROCYTE CULTURES
Primary astrocyte cultures were prepared from the cortex of
newborn (1–2 days) OF1 mice as described previously (Meme
et al., 2006). Briefly, cells were seeded into 100-mm diameter
plastic dishes (Nunc, Roskilde, Denmark) at the density of 3 ×
106 cells/dish in DMEM (Sigma-Aldrich, St-Louis MO, USA),
supplemented with penicillin (5 U/ml), streptomycin (5μg/ml)
(Invitrogen, Carlsbad, CA, USA) and 10% FCS (Hyclone, Logan,
UT, USA). The medium was changed twice a week. When cells
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reached confluence, around 10 days in vitro (DIV), they were
harvested with trypsin-EDTA (Invitrogen). Then, cells were re-
plated (2 × 105 cells per well), as secondary cultures, on glass
coverslips (Gassalem, Limeil-Brévannes, France) placed inside 16-
mm diameter 4 well plastic plates for hemichannel assay and on
35mm diameter petri dishes for scrape loading dye transfer tech-
nique. Finally, they were grown to confluence (about 1 week) and
the medium was changed twice a week until the experiments were
carried out.
ACUTE HIPPOCAMPAL SLICES
GFAP-eGFP mice (Nolte et al., 2001) were decapitated and their
brains were rapidly removed. Hippocampi were dissected and
placed in ice-cold artificial cerebrospinal fluid (ACSF) equili-
brated with 95% O2–5% CO2. Transverse hippocampal slices
(300–400μm thick) were cut on a vibroslicer (Leica VT 1000S,
Wetzlar, Germany) and transferred to a holding chamber where
they rested on a nylon mesh, submerged in oxygenated ACSF
at room temperature for a stabilization period of 45min before
recodings. The ACSF solution contained in mM: NaCl 134;
KCl 2.8; NaHCO3 29; NaH2PO4 1.1; glucose 12; MgSO4 1.5;
CaCl2 2.5.
DYE UPTAKE EXPERIMENTS
Hemichannel activity in cultured astrocytes was induced either by
treatment with two pro-inflammatory cytokines, TNF-α and IL-
1β (Retamal et al., 2007) or by exposing the cells to a Ca2+-free
solution (Stout et al., 2002). The hemichannel-permeable fluo-
rescent tracer ethidium bromide (Etd+, 314 Da) was applied for
10min at 4μM final concentration and at 37◦C. Then, cells were
washed with Hank’s balanced salt solution (HBSS) in mM: NaCl:
137; KCl: 5.4; Na2HPO4: 0.34; KH2PO4: 0.44, at pH 7.4 and sup-
plemented with 1.2mM CaCl2 (HBSS-Ca2+). Finally, astrocytes
were mounted in Fluoromount and examined by epifluores-
cence (518 nm excitation and 605 nm emission) using an inverted
microscope (Diaphot-Nikon, Nikon France S.A, Champigny sur
Marne) equipped with a CCD camera (Nikon) associated with
image analyzer software (Lucia-Nikon). Captured images of Etd+
uptake were analyzed with the Image J program (NIH software).
In slices derived from GFAP-eGFP mice, astrocytes were iden-
tified by GFP fluorescence and hemichannel activity was investi-
gated. In this mouse, not all astrocytes are GFP-positive (Nolte
et al., 2001; Houades et al., 2006) and Etd+ uptake was also
observed in cells that were not positive for GFP. These cells
could be GFP-negative astrocytes, neurons or microglial cells, in
which hemichannel activity has been reported (see for instance
Orellana et al., 2011). In order to be sure that we were quan-
tifying Etd+ uptake in astrocytes, in this study hemichannel
activity was only considered in GFP-positive cells. As previously
described (Giaume et al., 2012), living slices were incubated with
Etd+ for 10min at room temperature and at 4μM final concen-
tration. Slices were also treated for 3 h with lipopolysaccharide
(LPS, 1–100 ng/ml), a procedure know to activate microglial cells
and induce Cx43 hemichannel activity in astrocytes (Retamal
et al., 2007). Then, following the 10min incubation with Etd+,
slices were rinsed 15min in ACSF to stop dye uptake and
reduce background labeling before submerging them for 2 h in
fixing solution (4% paraformaldehyde in 0.12M buffer phos-
phate). Fixed slices were then rinsed in PBS and mounted in
Fluoromount-G medium until photomicrographs were taken.
Labeled cells were visualized with a 40x objective in a micro-
scope equipped with epifluorescence illumination and appro-
priate filters for Etd+ (excitation wavelength, 528 nm; emission
wavelength, 598 nm) and GFAP-eGFP (excitation wavelength,
488 nm; emission wavelength, 507 nm). Alternatively, immuno-
labeled astrocytes were examined at 63x and 20x with a confocal
laser-scanning microscope (Leica TBCS SP2). Stacks of consec-
utive confocal images taken at 1μm intervals were acquired
sequentially with two lasers (argon 488 nm for GFAP-eGFP and
561 nm for Etd+). Fluorescence was quantified in arbitrary units
(AU), Image J program (NIH software). Dye uptake intensity was
evaluated as the difference (F—F0) between the fluorescence (F)
from astrocytes (20—30 cells per slice) and the background flu-
orescence (F0) measured in the same field where no labeled cells
were detected. At least three fields were selected in every slice for
background evaluation.
DETERMINATION OF GAP JUNCTIONAL COMMUNICATION
Experiments were performed by using the scrape loading dye
transfer technique, as previously described (Meme et al., 2006).
Cells were incubated at room temperature for 10min in HEPES
buffered salt solution containing (in mM): NaCl, 140; KCl, 5.5;
CaCl2, 1.8; MgCl2, 1; glucose, 10; HEPES, 10 at pH 7.35. Cells
were then washed in calcium-free HEPES solution for 1min and
the scrape loading and dye transfer assay (see Giaume et al.,
2012) was carried out in the same calcium-free solution con-
taining Lucifer yellow CH (427 Da, 1mg/ml). After 1min, cells
were washed with the HEPES solution and Lucifer yellow loaded
in the cells was allowed to diffuse through gap junction chan-
nels for 8min. Photomicrographs were taken and data were
quantified using NIS Nikon software. In all experiments, the
fluorescence area of the first row of cells initially loaded, as
measured in the presence of the gap junction channel inhibitor
carbenoxolone (100μM, 10min), was subtracted from the total
fluorescence area.
TAT-Gap19 IN VIVO ADMINISTRATION
Two different approaches were used for in vivo delivery of TAT-
Gap19. For acute experiments, 4 months old C57Bl6 male mice
were subjected to intra-carotid injection of 45mg/kg TAT-Gap19
(GenScript, Pistcataway, NJ, US) dissolved in saline. After 1 h
the mice were deeply anesthetized with sodium pentobarbital
(120mg/kg intraperitoneally) and were transcardially perfused
with cold ice phosphate-buffered saline (PBS) followed by per-
fusion with 10% formalin (Sigma-Aldrich, Oakville, Canada).
Brains were removed and stored in 10% formalin and the
next day were cryoprotected in 30% sucrose in PBS solution.
Cortical brain sections, 10μm thick, were collected and mounted
sequentially on glass microscope slides. Immunohistochemistry
was performed on the sections as previously described (Ozog
et al., 2002; Nakase et al., 2004; Kozoriz et al., 2010). Tenμm
thick glass mounted sections were rehydrated in PBS and
then blocked in PBS pH 7.4 containing 0.3% Triton-X-100
(TX100, Fisher Scientific) and 2% bovine serum albumin (BSA;
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Invitrogen,Canada) for 1 h, and incubated overnight in PBS con-
taining 1.0% BSA, 0.3% TX100 and anti-TAT primary antibody
(1/100 dilution; Cat # CB0888, Cell Applications, Inc., USA). The
following day, the slices were washed with PBS (3 × 10min) and
subsequently incubated for 1 h with secondary antibody (anti-
mouse IgG tagged with Alexa 488;Molecular Probes, USA) in PBS
containing 1% BSA, 0.3% TX100. Slices were then rinsed 3 times
for 10min with PBS and mounted with ProLong Gold antifade
reagent with DAPI. Images were obtained using the same expo-
sure times on a Ziess Axiophot Epifluorescent microscope, Zeiss
Canada, Toronto).
For experiments with i.v. administration, 55mg/kg TAT-
Gap19 was injected via the tail vein to obtain an estimated
250μM concentration in the blood (assuming a blood volume
of 8% of the body weight). Twenty-four hours after injection
of the peptide, mice were deeply anesthetized by i.p. injec-
tion of ketamine (240mg/kg) and xylazine (12mg/kg) and were
transcardially perfused with PBS. Brains were removed, snap-
frozen in liquid nitrogen-cooled isopentane and mounted in
cryoprotectant (Klinipath) before storage at −80◦C. For stain-
ing, brains were sliced with a cryostat into 25μm thick coronal
sections, mounted on superfrost plus microscope slides (Thermo
Scientific) and fixed in 4% paraformaldehyde (25min, RT). Slices
were subsequently treated with PBS containing 0.2% TX100 (2 h,
RT), blocked with PBS containing 0.05% TX100 and 10% nor-
mal goat serum (NGS, 2 h, RT), and incubated overnight (4◦C)
with anti-TAT antibody (1/50 dilution, Cell Signaling Technology,
#2547S) in PBS containing 5% NGS and 0.05% TX100. The
following day, slices were washed with PBS and incubated for
2 h at room temperature with secondary antibody (1/200 anti-
mouse IgG linked to Alexa 488, Invitrogen Life Sciences) in
PBS containing 5% NGS and 0.05% TX100. Slides were then
rinsed with PBS and nuclei were counterstained with DAPI
(1μg/mL). Finally, slides were mounted in Vectashield mount-
ing medium (Vector Labs). Images were acquired using a BD
Pathway BioImaging System (Becton Dickinson) that includes
stitching software, obtaining a montage image of the entire
brain section. Intensity of Alexa 488 fluorescence in 10 analysis
zones in the left and right cortex respectively was analyzed using
ImageJ software.
TAT-Gap19 PEPTIDE
TAT-Gap19 (YGRKKRRQRRR-KQIEIKKFK) was synthesized by
Pepnome Inc. (Hongkong, China) at a purity of 95%. It was dis-
solved in PBS and aliquoted/stored as a stock solution of 10mM.
DATA ANALYSIS AND STATISTICS
The data are expressed as mean ± s.e.m., with “n” denoting
the number of independent experiments. Two groups were com-
pared by student’s t-test and two-tail p-value. In experiments
where the effects of different treatments were assessed on nor-
malized data, non-parametric ANOVA Kruskal-Wallis tests were
performed. Tests with significance of p < 0.05 were followed by
a Dunn’s multiple comparison post-hoc test using the GraphPad
Prism version 5.00 (San Diego, CA, USA). Unless stated oth-
erwise, significance as compared to control condition based on
the raw data (before normalization) was assessed by two-tailed
Wilcoxon signed-ranked tests. The level of significance was set
at p < 0.05. Graphics were prepared using Microcal Origin 6.0
(Northampton, MA, USA) and Adobe Illustrator 10 (San Jose,
CA, USA).
RESULTS
Recently, it was reported that Gap19 (KQIEIKKFK; see Figure 1)
inhibits Cx43 hemichannel activity but not gap junctional com-
munication in the heart (Wang et al., 2013b). To determine
whether these findings also apply for brain cells, especially astro-
cytes which predominantly express Cx43 (Ransom and Giaume,
2013), we tested the effect of this peptide on hemichannel activity
(Etd+ uptake and ATP release assays) and gap junctional commu-
nication (scrape loading and dye transfer) in two in vitro prepa-
rations: primary cultures of astrocytes and acute hippocampal
slices.
While in vivo astrocytes express two major Cxs, Cx43 and
Cx30, astrocytes in primary culture offer the advantage that
only one of them is expressed, namely Cx43 (Giaume et al.,
1991a). Indeed, Cx30 is detected in astrocytes only either after
10–11 weeks of solo-culture (Kunzelmann et al., 1999) or in
3 week-old astrocytes after 1 week of co-culture with neu-
rons (Koulakoff et al., 2008). Firstly, we tested whether Gap19
influences hemichannel activity in primary cultures of astro-
cytes stimulated by glutamate (100μM, 15min), a treatment
that has been reported to trigger hemichannel-mediated ATP
release in primary astrocytes (De Vuyst et al., 2009). As illustrated
in Figure 2, we found that Gap19 (30min treatment) inhibited
glutamate-triggered ATP release (Figure 2A). Alternatively, Cx43
hemichannel activity was also monitored by an Etd+ uptake assay
in astrocytes treated with a combination of two pro-inflammatory
cytokines, TNF-α and IL-1β (10 ng/ml for each, 3 h), a pro-
cedure that activates Cx43 hemichannels in cultured astrocytes
(Retamal et al., 2007). Under those conditions, we observed that
Etd+ uptake was inhibited in the presence of Gap19 in a dose-
dependent manner, with the peptide applied prior to (30min)
and during Etd+ uptake (Figures 2B,C). Finally, since in conflu-
ent cultures of astrocytes intercellular communication through
Cx43 gap junction channels is high (Giaume et al., 1991b),
we tested whether Gap19 (344μM and 688μM 30min) had
any effect on the level of gap junctional coupling. Experiments
performed with the scrape loading and dye transfer technique
demonstrated that Gap19 was without any effect on gap junc-
tional communication (Figures 1D1–D3 and summary bar chart)
in astrocytes which in culture express only Cx43 (see Koulakoff
et al., 2008).
The inhibitory effect of Gap19 in situ was then tested by per-
forming the Etd+ uptake assay in acute hippocampal brain slices
from GFAP-eGFP transgenic mice. While in normal saline solu-
tion Etd+ uptake was very weak, as reported previously (Orellana
et al., 2011), treatment of the slices with a Ca2+-free solution
(no added Ca2+ and 5mM of the Ca2+-buffer EGTA), a condi-
tion known to activate Cx43 hemichannels in astrocytes (Ye et al.,
2003) and that can be inhibited by carbenoxolone in hippocampal
slices (Rouach et al., 2008), induced Etd+ uptake in GFP-positive
cells. This increase in Etd+ uptake was not inhibited by Gap19
(applied 30min prior to and during Etd+ uptake) used at 172μM
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FIGURE 2 | Dose-dependent inhibition of ATP release and Etd+
uptake through Cx43 hemichannels by Gap19 with lack of effect
on gap junctional communication in cultured astrocytes. (A)
Concentration-dependent inhibition by Gap19 (30min pre-incubation) of
ATP release in cultured cortical astrocytes triggered by glutamate
(100μM, 15min application) (n = 6 independent experiments). (B)
Representative images showing Etd+ uptake (red) in cultured
astrocytes under control conditions (Ctrl) and after TNF-α/IL-1β or
TNF-α/IL-1β+ Gap19 treatment. Scale bar: 20μm. (∗p < 0.05;
∗∗∗p < 0.001). (C) Summary data of Etd+ uptake studies in astrocytes,
demonstrating inhibition by Gap19 (n = 5–8 independent experiments).
Statistical comparisons refer to the stimulus condition without Gap19
(zero Gap19 concentration). (D1–D3) Representative images of
scrape-loading dye transfer experiment in confluent cultures of
astrocytes. Compared to control condition (D1), with Gap19 344μM
(D2, 30min pre-incubation) or 688μM (D3, 30min pre-incubation).
Lower graph: Quantification of scrape-loading data indicating that
Gap19 did not influence gap junctional coupling as measured in
confluent cultures of astrocytes (from left to right, bars are from
control and the two tested concentrations of Gap19, respectively).
(n = 3–5 independent experiments).
while concentrations of 344 and 688μM inhibited the uptake of
Etd+ by GFP-positive cells (Figures 3A,B).
The possibility of in vivo application of hemichannel block-
ers was explored through peripheral administration of Gap19
linked to the TATmembrane translocationmotif at its N-terminal
end (TAT-Gap19) in adult mice. One hour after carotid injection
(45mg/kg), animals were sacrificed and the brain tissue prepared
for immunohistochemistry to localize TAT-Gap19 making use of
an antibody directed against the TAT sequence. Figure 4A shows
that following this treatment, TAT immunoreactivity was readily
detected throughout the brain as compared to the brain tissue of
mice that received the vehicle (PBS) only. Gap19 has an intra-
cellular target located on the C-terminal tail of Cx43 to which
it binds with a Kd of ∼2.5μM (Wang et al., 2013b), making it
possible that the peptide can be trapped and retained intracellu-
lary. We therefore tested whether administration of a single dose
of TAT-Gap19 i.v. (55mg/kg, giving an estimated ∼250μM con-
centration assuming distribution in the blood volume) resulted
in detectable peptide signal in the brain 24 h after administra-
tion, again based on TAT immunostaining. Figure 4B illustrates
the average data of such experiments, demonstrating that the
TAT-Gap19 signal was significantly above the background level,
indicating that TAT-Gap19 was retained in the brain tissue.
DISCUSSION
Gap19 is a peptide that corresponds to a sequence on the cyto-
plasmic loop (CL) of Cx43. Its sequence is part of the L2 domain
that is involved in interactions of the CL with the CT-tail of
Cx43. Interestingly, CT-CL interaction has a differential effect
on hemichannels and gap junction channels: it closes gap junc-
tion channels while it is necessary for hemichannel opening
(Ponsaerts et al., 2010; D’hondt et al., 2013; Iyyathurai et al., 2013;
Wang et al., 2013a,b). This differential effect is most probably the
consequence of distinct channel configurations of hemichannels
as compared to gap junction channels (Wang et al., 2013b).
Gap19 peptide binds to the CT and thereby prevents interac-
tion of the CT with the CL, making hemichannels unavailable
for opening (Wang et al., 2013a). Gap19 has most extensively
been characterized in C6 cells overexpressing Cx43 and in car-
diomyocytes (Wang et al., 2013a). We here demonstrate that
Gap19 also inhibits hemichannel activity in astrocytes while
not affecting gap junctional coupling. The concentrations neces-
sary to achieve hemichannel block in astrocytes appeared to be
somewhat higher than in Cx43-expressing C6 cells: in the lat-
ter, half-maximal inhibition of hemichannel opening triggered
by exposure to the Ca2+-ionophore A23187 occurred at ∼47μM
(Wang et al., 2013b) while the half-maximal effect concentration
was ∼142μM for glutamate-triggered ATP release in astrocyte
cultures (Figure 2A) and in the 250μM range when hemichan-
nels were opened with TNF-α/IL-1β in astrocyte cultures or with
zero extracellular Ca2+ in brain slices (Figure 3B). These dif-
ferences may relate to differences in the triggers used to induce
hemichannel opening (increase of intracellular Ca2+ vs. decrease
of extracellular Ca2+ or cytokine exposure) or differences in the
hemichannel assays used (patch clamp, ATP release, dye uptake).
Gap19 needs to enter the cell in order to reach its target located
on the CT-tail of Cx43; it is endowed with some intrinsic plasma
membrane-permeability that is related to the fact that 4 AAs of the
nonapeptide are positively charged Lys residues. However, linking
Gap19 to the HIV-derived TAT internalization sequence further
promotes its membrane permeability and reduces the concen-
tration for half-maximal inhibition of Cx43 hemichannels in C6
cells from∼47μM to∼7μM (Wang et al., 2013b), Supplemental
Data. This 7μM concentration is in good agreement with the
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FIGURE 3 | Gap19 inhibits hemichannel activity in astrocytes studied
in acute hippocampal slices. (A) Representative images of Etd+
uptake (red) in astrocytes (green) in hippocampal slices from
GFAP-eGFP transgenic mice, under control conditions (upper row) and
after 10min exposure to a Ca2+-free solution without (middle row) or
with (lower row) 344μM Gap19 treatment. Scale bar: 10μm. (B)
Summary graph demonstrating significant Etd+ uptake in astrocytes
that was inhibited by Gap19 used at concentration of 344 and 688μM.
Statistical comparisons in (B) were done with the stimulus condition
without Gap19 (n = 3 independent experiments; ∗∗∗p < 0.001).
FIGURE 4 | Detection of TAT-Gap19 in the cortex of the mouse. (A1–A2)
One hour after carotid injection of TAT-Gap19 the brain displayed clear TAT
immunoreactivity compared to mice that received vehicle (PBS) only. (A1),
Area in small box is enlarged in the lower right box of the panel; (A2), Double
labeling with anti-TAT and anti-GFAP antibodies indicates that some
GFAP-positive astrocytes (white arrows) have taken up the TAT peptide. Note
that the green fluorescence is concentrated in the white box area probably
because this represents a large vessel that would have more passage of
TAT-Gap19 into the brain parenchyma surrounding the vessel. (B) A single i.v.
injection of TAT-Gap19 gave significant immune signal in the brain 24 h later.
Taken together, these experiments indicate that TAT-Gap19 traverses the
blood-brain barrier and is retained in the cells. Fluorescence intensities of
Alexa 488 signal of the secondary antibody determined in slices
immunostained with a primary antibody directed against the TAT sequence.
Control represents experiments in mice injected with PBS vehicle (n = 5 for
control and TAT-Gap19; ∗p < 0.05).
∼6.5μM half-maximal inhibition of unitary Cx43 hemichannel
currents when Gap19 is dialyzed in the cell via the patch pipette.
Finally, the effects of Gap19 on hemichannel activity reported
here are similar to those previously described for Gap26 and
Gap27 that also blocks hemichannel activity in astrocytes induced
by LPS or pro-inflammatory treatments in culture astrocytes (see
Retamal et al., 2007; Froger et al., 2010) and in acute brain
slices treated with the amyloid peptide (Orellana et al., 2011).
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We have also published that carbenoxolone blocks hemichannel
activity induced by a calcium free solution (Rouach et al., 2008,
Supplementary Data Figure S5).
The in vivo injection experiments demonstrate that TAT-
Gap19 can be detected in the brain tissue, based on immunos-
taining for the TAT moiety of the peptide (Figure 4). This
observation indicates that TAT-Gap19 can successfully cross the
blood-brain barrier, which is expected as a result of the presence
of the TAT membrane translocation motif. We did not quantify
the immune signal in terms of estimates of the concentration
attained. However, the fact that there is still significant TAT-
Gap19 immune signal 24 h after a single i.v. injection indicates
that the peptide is retained for several hours in the cells, which
is plausible given the fact that the Kd for Gap19 interaction with
its target on the CT-tail is in the micromolar range (∼2.5μM).
Finally, double labeling with anti-TAT and anti-GFAP antibodies
indicates that the peptide reaches GFAP-positive astrocytes, how-
ever, several TAT-positive cells are apparently not GFAP-positive.
This is not surprising for experiments performed in the cortex
of adult mice where it is well known that only a few astrocytes
are GFAP-positive at this age (see for instance Nolte et al., 2001;
Houades et al., 2006). Consequently, we cannot exclude that the
TAT-peptide staining could also come from endothelial cells or
microglia that have both been reported to express Cx43 (Orellana
et al., 2011).
The L2 peptide, from which Gap19 is derived, is also a spe-
cific hemichannel blocker (Ponsaerts et al., 2010) but Gap19 has
the advantage that it is smaller and contains the most crucial
motif to engage in interactions with the target(s) on the CT-tail.
Stehberg and collaborators have used TAT-L2 for local injection in
the amygdala in in vivo animal studies on fear memory (Stehberg
et al., 2012). Their work demonstrated that fear memory was sup-
pressed by TAT-L2 and was rescued upon addition of a cocktail
of several proposed gliotransmitter substances, suggesting a role
of gliotransmitter release via astrocytic hemichannels. Of note,
both L2 and Gap19 (or their TAT-linked versions) are specific
not only for hemichannels but also for the Cx43 protein. The CL
and CT domains are very different between different connexin
species and in line with this, we found that Gap19 does not affect
Cx40 hemichannels (Wang et al., 2013a). Moreover, Gap19 does
not block Panx1 channels (Wang et al., 2013a), making Gap19 a
potentially powerful tool to decipher the role of astroglial Cx43
hemichannels in brain functions and pathologies (see Giaume
et al., 2013).
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